Results 171 to 180 of about 6,092 (260)

Decreased urinary excretion of norepinephrine and dopamine in autonomic synucleinopathies. [PDF]

Clin Auton Res
Goldstein DS, Sullivan P, Holmes C.
europepmc   +1 more source

Aliphatic Poly(Carbonate)s with Acid Responsive Release Mechanisms for Micellar Anti‐Tumor Drug Delivery

Macromolecular Rapid Communications, EarlyView.
Micellar systems based on biodegradable aliphatic polycarbonates and acid‐responsive triggers enhance drug solubility, stability, and tumor‐selective release. This review covers micelles with acid‐cleavable drug linkages and those that disassemble via acid‐sensitive functionalities.
Adrian V. Hauck, Lutz Nuhn
wiley   +1 more source

Chemoselective and stereoselective charge transfer dynamic quenching with triazacyclononane europium and terbium tetra-azatriphenylene complexes.

Dalton Trans
Wen X, Black DJ, Pal R, Parker D.
europepmc   +1 more source

Sulfur dioxide and glutathione promote acetaldehyde accumulation under aerobic conditions in a model wine system: Impacts on hydroxyl radical formation. [PDF]

Curr Res Food Sci
Wang J, Chang H, Wang J, Sun Y, Wang Q, Dai L, Ye Z, Han G.   +7 more
europepmc   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Fusion Molecules Between the STAT5b Inhibitor Stafib-2-CR and a Cereblon Ligand. [PDF]

ChemistryOpen
Münzel T, Seidenstücker KC, Protzel C, Berg A, Berg T.   +4 more
europepmc   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Tyrosinase Cross-Linked PEG Hydrogels with DAT and DATT as Artificial Substrates: Design, Structure, and Functions. [PDF]

Biomacromolecules
Racheva M, Basalo Lourido J, Gurdal EE, Herbst M, Bayar S, Radzik D, Bähr E, Zwies C, Neffe AT, Pietzsch M, Lendlein A, Wischke C.   +11 more
europepmc   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

Beyond Phenolics: Alternative Substrates for Type III Copper Enzymes. [PDF]

Chembiochem
Pretzler M, Rompel A.
europepmc   +1 more source